17,261 trials
Osteoarthritis, Knee
Primary: Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale — -2.89; -2.23 score on a scale — p=0.004
Esophagogastric Adenocarcinoma
Primary: Overall Response Rate, as Assessed by Radiographic Imaging — 3 Participants
Stage I Bladder Cancer AJCC v8 · Stage II Bladder Cancer AJCC v8 · Stage III Bladder Cancer AJCC v8
Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants
HIV-1
Primary: Cohorts 1 and 2: Pharmacokinetics (PK) of Rilpivirine (TMC278) as Measured by Maximum Observed Plasma Concentration at Steady State (Cmax,ss) — 109; 154; 238 nanograms…
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Advanced Solid Tumours
Primary: Cohort A (aST): Objective Response Rate (ORR). — 7.14 Percentage of participants
Postbariatric Hypoglycemia
Primary: Glucose Nadir After Mizagliflozin Dosing — 6.2; 4.0; 17.5; 31.5 mg/dL
Extraintestinal Pathogenic Escherichia Coli Prevention
Primary: Cohort 1: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Vaccination on Day 1 — 46; 54; 60; 15 Participants
Anemia · Kidney Failure, Chronic
Primary: Area Under the Serum Concentration-Time Curve Over Dosing Interval (AUC14d) (14 Days) — 15204.31; 11269.14; 28647.03; 10327.98 day*ng/mL
Cutaneous Lupus Erythematosus
Primary: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12 — -37.05; -42.76 percent change
Locally Advanced Pancreatic Adenocarcinoma
Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants
Syncope, Vasovagal
Primary: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test — 32; 27; 33; 35 Participants — p=0.521
HIV · Cancer
Primary: Best Response During the Treatment Period — 1; 3; 5; 7 participants
HRAS Gene Mutation · HNSCC
Primary: Objective Response Rate (ORR) in High Variable Allele Frequency (VAF) Population, as Assessed by Independent Review Facility (IRF) — 20.0 percentage of participants
Ileus · Post-Operative Adhesions
Primary: Change From Baseline in Extent and Severity of Intra-abdominal Adhesions Among Subjects Treated With LB1148 or Placebo — 20.3; 4.3; 4.0; 8.5 total extent and severity…